{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:02:15Z","timestamp":1789516935898,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The major anti-hypertensive (AHT) drug classes have been associated with differential risks of psychiatric disorders. However, existing data are limited largely to depression, and confounding variables have not always been controlled for. We sought to fill the evidence gap, using TriNetX Analytics, an electronic health records network. Amongst 58.6 million patients aged 18\u201390 years, patients prescribed a calcium channel blocker (CCB) were compared with those taking a diuretic, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or \u03b2-blocker. Cohorts were propensity score-matched for age, sex, race, and blood pressure. Over a 2-year exposure period, we measured the incidence and risk ratio of a first diagnosis (ICD-10 codes), or a recurrence, of psychotic, affective, and anxiety disorders, as well as substance use disorders and sleep disorders. Cohort sizes ranged from 33,734 to 322,814. CCBs were associated with a lower incidence of psychotic, affective, and anxiety disorders than \u03b2-blockers (risk ratios 0.69\u20130.99) and a higher incidence than ARBs (risk ratios 1.04\u20132.23) for both first and recurrent diagnoses. Comparisons of CCBs with ACEIs or diuretics showed smaller risk ratios that varied between disorders, and between first episode and recurrence. AHT classes were also associated with the incidence of substance use and sleep disorders. Results remained largely unchanged after more extensive cohort matching for additional potential confounders. In a secondary analysis, a comparison between ARBs and ACEIs showed lower rates of psychotic, affective, and substance use disorders with ARBs, but higher risks of anxiety and sleep disorders. In conclusion, AHT classes are differentially associated with the incidence of psychiatric disorders. ARBs show the most advantageous profile and \u03b2-blockers the least. The apparent beneficial effects of ARBs merit further study.<\/jats:p>","DOI":"10.1038\/s41398-021-01444-1","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T01:02:42Z","timestamp":1621990962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes"],"prefix":"10.1038","volume":"11","author":[{"given":"Lucy","family":"Colbourne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1126","authenticated-orcid":false,"given":"Paul J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1444_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/HYPERTENSIONAHA.116.08188","volume":"68","author":"AH Boal","year":"2016","unstructured":"Boal, A. H. et al. Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders. Hypertension 68, 1132\u20131138 (2016).","journal-title":"Hypertension"},{"key":"1444_CR2","doi-asserted-by":"publisher","unstructured":"Shaw, R. J. et al. The relationship between antihypertensive medications and mood disorders: analysis of linked healthcare data for 1.8 million patients. Psychol. Med. https:\/\/doi.org\/10.1017\/S0033291719004094 (2021).","DOI":"10.1017\/S0033291719004094"},{"key":"1444_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2019.08.075","volume":"259","author":"YY Cao","year":"2019","unstructured":"Cao, Y. Y. et al. Distinct effects of antihypertensives on depression in the real-world setting: a retrospective cohort study. J. Affect. Disord. 259, 386\u2013391 (2019).","journal-title":"J. Affect. Disord."},{"key":"1444_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamapsychiatry.2018.3907","volume":"76","author":"JF Hayes","year":"2019","unstructured":"Hayes, J. F. et al. Association of hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry 76, 382\u2013390 (2019).","journal-title":"JAMA Psychiatry"},{"key":"1444_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/acps.12957","volume":"139","author":"LV Kessing","year":"2019","unstructured":"Kessing, L. V. et al. New drug candidates for depression: a nationwide population-based study. Acta Psychiatr. Scand. 139, 68\u201377 (2019).","journal-title":"Acta Psychiatr. Scand."},{"key":"1444_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.31887\/DCNS.2019.21.3\/trobbins","volume":"21","author":"LV Kessing","year":"2019","unstructured":"Kessing, L. V. et al. New drug candidates for bipolar disorder\u2014a nationwide population-based study. Bipolar Disord. 21, 301\u2013318 (2019).","journal-title":"Bipolar Disord."},{"key":"1444_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.120.15605","volume":"76","author":"LV Kessing","year":"2020","unstructured":"Kessing, L. V. et al. Antihypertensive drugs and risk of depression. A nationwide population-based study. Hypertension 76, 1263\u20131279 (2020).","journal-title":"Hypertension"},{"key":"1444_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41371-020-0303-y","volume":"34","author":"B Agustini","year":"2020","unstructured":"Agustini, B. et al. The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. J. Hum. Hypertens. 34, 787\u2013794 (2020).","journal-title":"J. Hum. Hypertens."},{"key":"1444_CR9","doi-asserted-by":"publisher","first-page":"e1317","DOI":"10.1097\/MD.0000000000001317","volume":"94","author":"Z Li","year":"2015","unstructured":"Li, Z., Li, Y., Chen, L., Chen, P. & Hu, Y. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine 94, e1317 (2015).","journal-title":"Medicine"},{"key":"1444_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","volume":"8","author":"M Taquet","year":"2021","unstructured":"Taquet, M. et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8, 416\u2013427 (2021).","journal-title":"Lancet Psychiatry"},{"key":"1444_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening The Reporting Of Observational Studies In Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"1444_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/mp.2016.86","volume":"21","author":"A Cipriani","year":"2016","unstructured":"Cipriani, A. et al. A systematic review of calcium channel antagonists in bipolar disorder, and some considerations regarding their future development. Mol. Psychiatry 21, 1324\u20131332 (2016).","journal-title":"Mol. Psychiatry"},{"key":"1444_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2015.09.002","volume":"134","author":"S Heyes","year":"2015","unstructured":"Heyes, S. et al. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog. Neurobiol. 134, 36\u201354 (2015).","journal-title":"Prog. Neurobiol."},{"key":"1444_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1192\/bjp.2019.157","volume":"216","author":"PJ Harrison","year":"2020","unstructured":"Harrison, P. J., Tunbridge, E. M., Dolphin, A. C. & Hall, J. Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal. Br. J. Psychiatry 216, 250\u2013253 (2020).","journal-title":"Br. J. Psychiatry"},{"key":"1444_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/ APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71, 1269\u20131324 (2018).","journal-title":"Hypertension"},{"key":"1444_CR16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133124 (2018).","journal-title":"Eur. Heart J."},{"key":"1444_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivar. Behav. Res."},{"key":"1444_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","volume":"314","author":"JS Haukoos","year":"2015","unstructured":"Haukoos, J. S. & Lewis, R. J. The propensity score. JAMA 314, 1637\u20131638 (2015).","journal-title":"JAMA"},{"key":"1444_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/0269881120936501","volume":"34","author":"PJ Harrison","year":"2020","unstructured":"Harrison, P. J., Luciano, S. & Colbourne, L. C. Rates of delirium associated with calcium channel blockers compared to diuretics, renin-angiotensin system agents, and beta-blockers: an electronic health records network study. J. Psychopharmacol. 34, 848\u2013855 (2020).","journal-title":"J. Psychopharmacol."},{"key":"1444_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/EDE.0000000000000504","volume":"27","author":"BF Arnold","year":"2016","unstructured":"Arnold, B. F., Ercumen, A., Benjamin-Chung, J. & Colford, J. M. Jr. Negative controls to detect selection bias and measurement bias in epidemiologic studies. Epidemiology 27, 637\u2013641 (2016).","journal-title":"Epidemiology"},{"key":"1444_CR21","doi-asserted-by":"publisher","unstructured":"Harrison P. J., Colbourne L., Luciano S. Incidence of neurodegenerative and cerebrovascular diseases associated with anti-hypertensive drug classes: a study of 34 million patients. Br. J. Psychiatry https:\/\/doi.org\/10.1192\/bjp.2020.249 (2021).","DOI":"10.1192\/bjp.2020.249"},{"key":"1444_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00592-013-0547-x","volume":"51","author":"AJ Ahola","year":"2014","unstructured":"Ahola, A. J., Harjutsalo, V., Forsblom, C. & Groop, P. H. Renin-angiotensin-aldosterone blockade is associated with decreased use of antidepressant therapy in patients with type I diabetes and diabetic nephropathy. Acta Diabetol. 51, 529\u2013533 (2014).","journal-title":"Acta Diabetol."},{"key":"1444_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","volume":"29","author":"L Rouch","year":"2015","unstructured":"Rouch, L. et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 29, 113\u2013130 (2015).","journal-title":"CNS Drugs"},{"key":"1444_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0004867417721654","volume":"52","author":"DJ Brownstein","year":"2018","unstructured":"Brownstein, D. J. et al. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust. NZ J. Psychiatry 52, 24\u201338 (2018).","journal-title":"Aust. NZ J. Psychiatry"},{"key":"1444_CR25","doi-asserted-by":"publisher","first-page":"E876","DOI":"10.3390\/ijms19030876","volume":"19","author":"L Jackson","year":"2018","unstructured":"Jackson, L., Eldahshan, W., Fagan, S. C. & Ergul, A. Within the brain: the renin angiotensin system. Int. J. Mol. Sci. 19, E876 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1444_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.biopsych.2014.04.004","volume":"75","author":"A Shekhar","year":"2014","unstructured":"Shekhar, A. Angiotensin type I receptor antagonists\u2014a novel approach to augmenting posttraumatic stress disorder and phobia therapies? Biol. Psychiatry 75, 836\u2013837 (2014).","journal-title":"Biol. Psychiatry"},{"key":"1444_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.biopsych.2019.04.010","volume":"86","author":"E Pulcu","year":"2019","unstructured":"Pulcu, E. et al. The effects of the angiotensin II receptor antagonist losartan on appetitive versus aversive learning: a randomized controlled trial. Biol. Psychiatry 86, 397\u2013404 (2019).","journal-title":"Biol. Psychiatry"},{"key":"1444_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.biopsych.2019.09.026","volume":"86","author":"DM Stout","year":"2019","unstructured":"Stout, D. M. & Risburgh, V. B. Angiotensin II signaling and fear extinction: translational evidence and novel receptor targets. Biol. Psychiatry 86, 874\u2013876 (2019).","journal-title":"Biol. Psychiatry"},{"key":"1444_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41386-020-00923-1","volume":"46","author":"A Seligowski","year":"2021","unstructured":"Seligowski, A. et al. The renin-angiotensin system in PTSD: a replication and extension. Neuropsychopharmacology 46, 750\u2013755 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"1444_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/jama.1986.03370030077031","volume":"255","author":"J Avery","year":"1986","unstructured":"Avery, J., Everitt, D. E. & Weiss, S. Increased antidepressant use in patients prescribed \u03b2-blockers. JAMA 255, 357\u2013360 (1986).","journal-title":"JAMA"},{"key":"1444_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3389\/fphar.2019.00973","volume":"10","author":"MS Ali","year":"2019","unstructured":"Ali, M. S. et al. Propensity score methods in health technology assessment: principles, extended applications, and recent advances. Front. Pharmacol. 10, 973 (2019).","journal-title":"Front. Pharmacol."},{"key":"1444_CR32","doi-asserted-by":"publisher","unstructured":"Davis, K. A. S. et al. Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health. Lancet Psychiatry. https:\/\/doi.org\/10.1016\/S2215-0366(19)30298-6.","DOI":"10.1016\/S2215-0366(19)30298-6"},{"key":"1444_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey, J. A., Schwartz, B. S., Stewart, W. F. & Adler, N. A. Using electronic health records for population health research: a review of methods and applications. Annu. Rev. Public Health 37, 61\u201381 (2016).","journal-title":"Annu. Rev. Public Health"},{"key":"1444_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","volume":"106","author":"MR Cowie","year":"2017","unstructured":"Cowie, M. R. et al. Electronic health records to facilitate clinical research. Clin. Res. Cardiol. 106, 1\u20139 (2017).","journal-title":"Clin. Res. Cardiol."},{"key":"1444_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0272989X20954403","volume":"41","author":"GB Taksler","year":"2021","unstructured":"Taksler, G. B. et al. Opportunities, pitfalls, and alternatives in adapting electornic health records for health services research. Med. Decis. Mak. 41, 133\u2013142 (2021).","journal-title":"Med. Decis. Mak."},{"key":"1444_CR36","doi-asserted-by":"publisher","unstructured":"Harrison, P. J., Hall, N., Mould, A., Al-Juffali N. & Tunbridge, E. M. Cellular calcium in bipolar disorder: systematic review and meta-analysis. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-019-0622-y (2019).","DOI":"10.1038\/s41380-019-0622-y"},{"key":"1444_CR37","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi, G. W., Striessnig, J., Koschak, A. & Dolphin, A. C. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol. Rev. 67, 821\u2013870 (2015).","journal-title":"Pharmacol. Rev."},{"key":"1444_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3175-0","volume":"20","author":"LZ Atkinson","year":"2019","unstructured":"Atkinson, L. Z. et al. The Oxford study of calcium channel antagonism, cognition, mood instability and sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study. Trials 20, 120 (2019).","journal-title":"Trials"},{"key":"1444_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41380-019-0583-1","volume":"25","author":"MB Clark","year":"2020","unstructured":"Clark, M. B. et al. Long-range sequencing reveals the splicing profile of the calcium channel gene CACNA1C in human brain. Mol. Psychiatry 25, 37\u201347 (2020).","journal-title":"Mol. Psychiatry"},{"key":"1444_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0916-3","volume":"15","author":"J Vian","year":"2017","unstructured":"Vian, J. et al. The renin-angiotensin system: a possible new target for depression. BMC Med. 15, 144 (2017).","journal-title":"BMC Med."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01444-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01444-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01444-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T08:13:10Z","timestamp":1669882390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01444-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["1444"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01444-1","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L. is an employee of TriNetX Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"319"}}